Biotech Stock Mailbag: Genta Takes Another Stab

BOSTON, Mass. (TheStreet) -- The Biotech Stock Mailbag is open for business. Let's kick things off with an email about Genta(GETA.OB).

"What is your opinion on Genta's Genasense phase III results in the fourth quarter," asks Joan. "Do you believe their biomarker approach on low-normal LDH will achieve the holy grail p-value of 0.05 that [FDA] is looking for to approve the drug?"

Genta is such a blast from the past. I haven't given the company much thought or coverage since 2004 when Genasense's phase III melanoma study was voted down by the FDA's cancer drug advisory committee meeting. ...